[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT03141021":3,"trial-entities:NCT03141021":212,"trial-summary:NCT03141021":216},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":6,"overall_status":7,"completion_date":8,"status_verified_date":9,"last_update_date":10,"start_date":11,"sponsor_name":12,"lead_sponsor_class":13,"has_dmc":14,"brief_summary":15,"detailed_description":16,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":16,"phases":21,"enrollment_info":22,"interventions":25,"primary_outcomes":26,"secondary_outcomes":41,"sex":42,"minimum_age":16,"maximum_age":16,"healthy_volunteers":14,"eligibility_criteria":43,"std_ages":48,"locations":52,"central_contacts":203,"overall_officials":205,"references":207,"see_also_links":208},"NCT03141021","201702006","Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors","RECRUITING","2053-04-30","2026-03","2026-03-09","2017-04-28","Washington University School of Medicine","OTHER",false,"First, the investigators plan to use a retrospective analysis to determine the clinical landscape of neurofibromatosis (NF)1-associated malignant peripheral nerve sheath tumor (MPNST) and precursor lesions (e.g., atypical or nodular plexiform neurofibromas). A worldwide database will be established, collecting, in a standardized manner, histologic, immunohistochemical, molecular, radiographic, treatment, and related clinical data from centers worldwide with expertise in these NF1-related cancers. Although retrospective in nature, the resulting data from this registry may reveal previously unanticipated patterns, similar to the INFACT effort outcome. This registry would then allow the acquisition of data associated with MPNST biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing data for aggregate analyses). Second, the investigators plan to co-register patients to institutional banks in order to prospectively collect MPNST samples for analysis. These patients will be consented in order to collect the above information and for banking of tumor tissue and future studies that include genomic characterization of the tumors.",null,[18],"Malignant Peripheral Nerve Sheath Tumors",[],"OBSERVATIONAL",[],{"count":23,"type":24},1050,"ESTIMATED",[],[27,31,33,35,37,39],{"measure":28,"description":29,"timeFrame":30},"Histologic characteristics of malignant peripheral nerve sheath tumor (MPNST)","-The data collected through this registry will be used to analyze previously unanticipated patterns and prognostic clues about MPNST","10 years",{"measure":32,"description":29,"timeFrame":30},"Immunohistochemical characteristics of malignant peripheral nerve sheath tumor (MPNST)",{"measure":34,"description":29,"timeFrame":30},"Molecular characteristics of malignant peripheral nerve sheath tumor (MPNST)",{"measure":36,"description":29,"timeFrame":30},"Radiographic characteristics of malignant peripheral nerve sheath tumor (MPNST)",{"measure":38,"description":29,"timeFrame":30},"Treatment given to patients with malignant peripheral nerve sheath tumor (MPNST)",{"measure":40,"description":29,"timeFrame":30},"Future genomic characterization of malignant peripheral nerve sheath tumor (MPNST)",[],"ALL",{"inclusion":44,"exclusion":46,"raw_text":47},[45],"Any patient diagnosed with an MPNST is eligible for enrollment to this registry provided s\u002Fhe consents to participate (or consent form his\u002Fher parent or legal guardian or legally authorized representative is obtained).",[],"Inclusion Criteria and Exclusion Criteria:\n\n-Any patient diagnosed with an MPNST is eligible for enrollment to this registry provided s\u002Fhe consents to participate (or consent form his\u002Fher parent or legal guardian or legally authorized representative is obtained).",[49,50,51],"CHILD","ADULT","OLDER_ADULT",[53,63,78,92,101,109,131,143,151,159,174,181,195],{"facility":54,"status":55,"city":56,"state":57,"zip":58,"country":59,"geoPoint":60},"Moffitt Cancer Center","COMPLETED","Tampa","Florida","33612","United States",{"lat":61,"lon":62},27.94752,-82.45843,{"facility":64,"status":7,"city":65,"state":66,"zip":67,"country":59,"contacts":68,"geoPoint":75},"Johns Hopkins","Baltimore","Maryland","21205",[69,73],{"name":70,"role":71,"phone":72},"Christine Pratilas, M.D.","CONTACT","410-955-8751",{"name":70,"role":74},"PRINCIPAL_INVESTIGATOR",{"lat":76,"lon":77},39.29038,-76.61219,{"facility":79,"status":80,"city":81,"state":66,"zip":82,"country":59,"contacts":83,"geoPoint":89},"National Institutes of Health (NIH)","NOT_YET_RECRUITING","Bethesda","20892",[84,88],{"name":85,"role":71,"phone":86,"email":87},"Jack F Shern, M.D.","301-402-1444","john.shern@nih.gov",{"name":85,"role":74},{"lat":90,"lon":91},38.98067,-77.10026,{"facility":93,"status":94,"city":95,"state":96,"zip":97,"country":59,"geoPoint":98},"Dana Farber Cancer Institute","WITHDRAWN","Boston","Massachusetts","02215",{"lat":99,"lon":100},42.35843,-71.05977,{"facility":102,"status":94,"city":103,"state":104,"zip":105,"country":59,"geoPoint":106},"University of Minnesota","Minneapolis","Minnesota","55455",{"lat":107,"lon":108},44.97997,-93.26384,{"facility":12,"status":7,"city":110,"state":111,"zip":112,"country":59,"contacts":113,"geoPoint":128},"St Louis","Missouri","63110",[114,118,119,122,124,126],{"name":115,"role":71,"phone":116,"email":117},"Angela Hirbe, M.D., Ph.D.","(314) 362-8965","hirbea@wustl.edu",{"name":115,"role":74},{"name":120,"role":121},"David Gutmann, M.D., Ph.D.","SUB_INVESTIGATOR",{"name":123,"role":121},"Sonika Dahiya, M.D., MBBS",{"name":125,"role":121},"Brian Van Tine, M.D., Ph.D.",{"name":127,"role":121},"Peter Oppelt, M.D.",{"lat":129,"lon":130},38.62727,-90.19789,{"facility":132,"status":80,"city":133,"state":133,"zip":134,"country":59,"contacts":135,"geoPoint":140},"Memorial Sloan Kettering Cancer Center","New York","10065",[136,139],{"name":137,"role":71,"phone":138},"Ping Chi, M.D., Ph.D.","646-888-4166",{"name":137,"role":74},{"lat":141,"lon":142},40.71427,-74.00597,{"facility":144,"status":55,"city":145,"state":146,"zip":147,"country":59,"geoPoint":148},"Lifespan","Providence","Rhode Island","02903",{"lat":149,"lon":150},41.82399,-71.41283,{"facility":152,"status":55,"city":153,"state":154,"zip":155,"country":59,"geoPoint":156},"University of Utah","Salt Lake City","Utah","84112",{"lat":157,"lon":158},40.76078,-111.89105,{"facility":160,"status":7,"city":161,"state":162,"zip":163,"country":164,"contacts":165,"geoPoint":171},"Mount Sinai","Toronto","Ontario","M5T 3L9","Canada",[166,170],{"name":167,"role":71,"phone":168,"email":169},"Jay Wunder, M.D.","416-586-5995","jay.wunder@sinaihealthsystem.ca",{"name":167,"role":74},{"lat":172,"lon":173},43.70643,-79.39864,{"facility":175,"status":55,"city":176,"country":177,"geoPoint":178},"Global Gene Corporation","Mumbai","India",{"lat":179,"lon":180},19.07283,72.88261,{"facility":182,"status":7,"city":183,"state":184,"country":185,"contacts":186,"geoPoint":192},"Nagoya University Hospital","Nagoya","Showa Ward","Japan",[187,191],{"name":188,"role":71,"phone":189,"email":190},"Yoshihiro Nishida, M.D., Ph.D.","+81 52-741-2111","ynishida@med.nagoya-u.ac.jp",{"name":188,"role":74},{"lat":193,"lon":194},35.18147,136.90641,{"facility":196,"status":197,"city":198,"country":199,"geoPoint":200},"Royal National Orthopedic Hospital","TERMINATED","London","United Kingdom",{"lat":201,"lon":202},51.50853,-0.12574,[204],{"name":115,"role":71,"phone":116,"email":117},[206],{"name":115,"affiliation":12,"role":74},[],[209],{"label":210,"url":211},"Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine","http:\u002F\u002Fwww.siteman.wustl.edu",{"nct_id":4,"conditions":213,"biomarkers":215},[214],"Malignant Peripheral Nerve Sheath Tumor",[],{"nct_id":4,"found":217,"summary":218,"prompt_version":228},true,{"design":219,"status":220,"heading":221,"summary":222,"follow_up":223,"word_count":224,"commitments":225,"compensation":226,"drugs_mentioned":227},"This is an observational study, meaning researchers are collecting information without giving any specific treatments. It aims to enroll 1050 participants.","completed","Registry for Malignant Peripheral Nerve Sheath Tumors","This study is creating a worldwide database to better understand Malignant Peripheral Nerve Sheath Tumors (MPNSTs), especially those linked to Neurofibromatosis type 1 (NF1). Researchers are collecting information like tissue characteristics (histologic), immune markers (immunohistochemical), and genetic details (molecular) from patients with MPNSTs. They hope to find new patterns in how these tumors develop and behave. You can join if you have been diagnosed with an MPNST and agree to share your information. The study aims to collect data from 1050 participants over 10 years to learn more about MPNSTs.","The study will collect information on your tumor's characteristics for up to 10 years.",90,"Not specified in the trial record.","Not stated in the trial record.",[],"v2"]